BR0212892A - Derivados de 4-pirimidona-3-substituìdo - Google Patents

Derivados de 4-pirimidona-3-substituìdo

Info

Publication number
BR0212892A
BR0212892A BR0212892-6A BR0212892A BR0212892A BR 0212892 A BR0212892 A BR 0212892A BR 0212892 A BR0212892 A BR 0212892A BR 0212892 A BR0212892 A BR 0212892A
Authority
BR
Brazil
Prior art keywords
substituted
ring
pyrimidone
group
atom
Prior art date
Application number
BR0212892-6A
Other languages
English (en)
Inventor
Fumiaki Uehara
Keiichi Aritomo
Aya Shoda
Shinsuke Hiki
Masahiro Okuyama
Yoshihiro Usui
Mitsuru Ooizumi
Kazutoshi Watanabe
Original Assignee
Mitsubishi Pharma Corp
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, Sanofi Synthelabo filed Critical Mitsubishi Pharma Corp
Publication of BR0212892A publication Critical patent/BR0212892A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE 4-PIRIMIDONA-3-SUBSTITUìDO". Um derivado de pirimidona representado pela fórmula (I) ou um sal do mesmo, ou um solvato do mesmo, ou um hidrato do mesmo tendo atividade inibitória contra proteína tau quinase 1: em que R^ 1^ representa um grupo alquil C~ 1~-C~ 12~ que pode ser substituído; R representa, por exemplo, um grupo representado pela seguinte fórmula (II): em que R^ 2^ e R^ 3^ representam independentemente um átomo de hidrogênio ou um grupo alquil C~ 1~-C~ 8~; R^ 4^ representa um anel benzeno que pode ser substituído, um anel naftaleno que pode ser substituído, um anel indano que pode ser substituído, um anel tetrahlidronaftaleno que pode ser substituído, ou um anel heterocíclico opcionalmente substituído tendo de 1 a 4 hétero-átomos selecionados no grupo que consiste de átomo de oxigênio, átomo de enxofre e átomo de nitrogênio, e tendo de 5 a 10 átomos constituintes de anel no total.
BR0212892-6A 2001-09-21 2002-09-20 Derivados de 4-pirimidona-3-substituìdo BR0212892A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001331675 2001-09-21
JP2001331674 2001-09-21
JP2001331677 2001-09-21
JP2001331678 2001-09-21
PCT/JP2002/009685 WO2003037888A1 (en) 2001-09-21 2002-09-20 3-substituted-4-pyrimidone derivatives

Publications (1)

Publication Number Publication Date
BR0212892A true BR0212892A (pt) 2004-08-03

Family

ID=27482651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212892-6A BR0212892A (pt) 2001-09-21 2002-09-20 Derivados de 4-pirimidona-3-substituìdo

Country Status (24)

Country Link
US (1) US7427615B2 (pt)
EP (1) EP1427720B1 (pt)
JP (1) JP4347050B2 (pt)
KR (1) KR100881821B1 (pt)
CN (1) CN100488958C (pt)
AT (1) ATE424393T1 (pt)
AU (1) AU2002337499B2 (pt)
BR (1) BR0212892A (pt)
CA (1) CA2460121C (pt)
CY (1) CY1110317T1 (pt)
DE (1) DE60231414D1 (pt)
DK (1) DK1427720T3 (pt)
EA (1) EA007576B1 (pt)
ES (1) ES2323576T3 (pt)
HU (1) HUP0401900A3 (pt)
IL (2) IL160700A0 (pt)
MX (1) MXPA04002662A (pt)
NO (1) NO325781B1 (pt)
NZ (1) NZ531636A (pt)
PL (1) PL368671A1 (pt)
PT (1) PT1427720E (pt)
SI (1) SI1427720T1 (pt)
TW (1) TWI265164B (pt)
WO (1) WO2003037888A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
DE60208051T2 (de) 2001-09-21 2006-06-22 Sanofi-Aventis 3-substituierte-4-pyrimidonderivate
BR0316785A (pt) 2002-12-16 2005-10-25 Mitsubishi Pharma Corp Derivados de 4-pirimidona-3-substituìdos
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
AU2004265341A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN102140090A (zh) 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
TW200621760A (en) * 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
ES2359071T3 (es) * 2004-09-29 2011-05-18 Mitsubishi Tanabe Pharma Corporation Derivados de 6-(piridinil)-4-pirimidona como inhibidores de la proteina tau cinasa 1.
JP2008516945A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
WO2006041405A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
ES2373587T3 (es) * 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2193129B1 (en) * 2007-09-14 2012-10-24 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-2-one derivative
AU2008297814A1 (en) * 2007-09-14 2009-03-19 Sanofi-Aventis 3-Methyl-2- ( (2S) -2- (4- (3-Methyl-1, 2, 4-Oxadiazol-5-YL) phenyl) morpholino) -6- (pyrimidin-4-yl) Pyrimidin-4 (3H) -one as tau protein kinase inhibitor
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US8940738B2 (en) 2009-08-13 2015-01-27 Mitsubishi Tanabe Pharma Corporation Pyrimidone compounds
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
BR112017006232B1 (pt) 2014-09-29 2022-10-11 Chemocentryx, Inc. Processos e intermediários na preparação de antagonistas de c5ar
BR112018014222A2 (pt) 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935631B1 (pt) 1970-12-28 1974-09-25
JPS559099B2 (pt) 1972-08-07 1980-03-07
JPS4935633A (pt) 1972-08-09 1974-04-02
JPS4935632A (pt) 1972-08-10 1974-04-02
JPS5124008B2 (pt) 1972-08-10 1976-07-21
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE58908208D1 (de) 1988-07-29 1994-09-22 Ciba Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate.
ATE386115T1 (de) 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
JPH07179442A (ja) * 1993-10-08 1995-07-18 Sagami Chem Res Center ４−イミノオキサゾリジン−２−オン誘導体、それらの製造方法、及びそれらを有効成分とする除草剤
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
CZ296911B6 (cs) 1996-12-05 2006-07-12 Amgen Inc. Substituovaný pyrimidin, jeho pouzití a farmaceutický prostredek na jeho bázi
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
MXPA02008240A (es) 2000-02-25 2002-11-29 Hoffmann La Roche Moduladores del receptor de adenosina.
WO2001070728A1 (en) 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
DE60208051T2 (de) 2001-09-21 2006-06-22 Sanofi-Aventis 3-substituierte-4-pyrimidonderivate
BR0316785A (pt) 2002-12-16 2005-10-25 Mitsubishi Pharma Corp Derivados de 4-pirimidona-3-substituìdos
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
EA200400453A1 (ru) 2004-08-26
CN1556804A (zh) 2004-12-22
HUP0401900A2 (hu) 2004-12-28
PL368671A1 (en) 2005-04-04
PT1427720E (pt) 2009-04-27
NO20041600L (no) 2004-06-16
KR100881821B1 (ko) 2009-02-03
CA2460121A1 (en) 2003-05-08
CN100488958C (zh) 2009-05-20
WO2003037888A1 (en) 2003-05-08
ATE424393T1 (de) 2009-03-15
KR20040054689A (ko) 2004-06-25
JP4347050B2 (ja) 2009-10-21
ES2323576T3 (es) 2009-07-21
AU2002337499B2 (en) 2007-08-23
EP1427720B1 (en) 2009-03-04
EP1427720A1 (en) 2004-06-16
CA2460121C (en) 2010-11-02
NO325781B1 (no) 2008-07-14
US20050090490A1 (en) 2005-04-28
HUP0401900A3 (en) 2005-08-29
NZ531636A (en) 2005-11-25
TWI265164B (en) 2006-11-01
IL160700A (en) 2009-09-22
DE60231414D1 (de) 2009-04-16
SI1427720T1 (sl) 2009-08-31
JP2005510506A (ja) 2005-04-21
IL160700A0 (en) 2004-08-31
MXPA04002662A (es) 2004-11-22
EA007576B1 (ru) 2006-12-29
CY1110317T1 (el) 2015-01-14
DK1427720T3 (da) 2009-05-04
US7427615B2 (en) 2008-09-23

Similar Documents

Publication Publication Date Title
BR0212892A (pt) Derivados de 4-pirimidona-3-substituìdo
BR0212893A (pt) Derivados de 4-pirimidona-3-substituìdo
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
BR0207863A (pt) Inibidores piridìnicos de metaloproteinases da matriz
BR0313178A (pt) Derivados de pirazol e processo para a produção destes
BR0316785A (pt) Derivados de 4-pirimidona-3-substituìdos
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60302558D1 (de) 5-substituierte alkylaminopyrazol-derivative als pestizide
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
WO2003045901A3 (en) Guanidine derivatives
HUP0102515A2 (hu) Ciklopeptidek, eljárás előállításukra, hatóanyagként azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE233252T1 (de) Substituierte dihydrobenzofurane als pde- hemmstoffe
BR0311410A (pt) Composto de piperidina
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
NO20043211L (no) Imidazo [1,2-a]pyridinderivat
BR0307424A (pt) Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários
DE60318089D1 (de) Protein-tyrosine-kinase-inhibitoren
ATE380028T1 (de) Mittel zur anregung des appetits und mittel zur behandlung von anorexie
TH102358A (th) อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3
BR0009856A (pt) Sìntese de 3-amino-3-aril propanoatos
BRPI0412253A (pt) derivados de nicotinamida úteis como inibidores de pde4
TH102358B (th) อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1849 DE 13/06/2006 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B25D Requested change of name of applicant approved

Owner name: MITSUBISHI PHARMA CORPORATION (JP) , SANOFI-AVENTI

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements